Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts

Diagnostic Molecular Pathology

Volumn 15, Issue 1, 2006, Pages 56-61

  Arocho, Alaina ^a   Chen, Beiyun ^a   Ladanyi, Marc ^a   Pan, Qiulu ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

2 Ct calculation; Chronic myelogenous leukemia; Quantitative PCR standard curve

Indexed keywords

BCR ABL PROTEIN; CHIMERIC PROTEIN; MESSENGER RNA; PLASMID DNA; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PROTEIN TYROSINE KINASE; RNA;

ARTICLE; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CONTAMINATION; DATA ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECIPROCAL CHROMOSOME TRANSLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; GENETIC TRANSCRIPTION; GENETICS; STATISTICAL ANALYSIS; VALIDATION STUDY;

DATA INTERPRETATION, STATISTICAL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC;

EID: 33645672106     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200603000-00009     Document Type: Article

References (21)

1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343.
2. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer program. Leukemia. 2003;17:2318-2357.
3. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990-999.
4. Kim YJ, Kim DW, Lee S, et al. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. Bone Marrow Transplant. 2004;33:535-542.
5. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol. 2003;40(2 Suppl 2):62-68.
6. Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) during imatinib treatment. Leukemia. 2003;17:1700-1706.
7. Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol. 2003;70:1-10.
8. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17:2392-2400.
9. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401-2409.
10. Le Coutre P, Kreuzer KA, Na IK, et al. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol. 2003;73:249-255.
11. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol. 2002;29:23-39.
12. van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013-1034.
13. Jones CD, Yeung C, Zehnder JL. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol. 2003;120:42-48.
14. Guo JQ, Lin H, Kantarjian H, et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia. 2002;16:2447-2453.
15. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia. 1999;13:957-964.
16. Pine SR, Moy FH, Wiemels JL, et al. Real-time quantitative PCR: Standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Polymerase chain reaction. J Pediatr Hematol Oncol. 2003;25:103-108.
17. Kolb EA, Pan Q, Ladanyi M, et al. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer. 2003;98:2643-2650.
18. Amabile M, Giannini B, Testoni N, et al. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica. 2001;86:252-259.
19. Drunat S, Olivi M, Brunie G, et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;114:281-289.
20. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative per and the 2-ΔΔCt method. Methods. 2001;25:402-440.
21. Bagg A. Chronic myeloid leukemia: A minimalistic view of post-therapeutic monitoring. J Mol Diagn. 2002;4:1-10.